Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children’s Oncology Group

Kubaney HR, Montgomery KE, Guidry L, Okada M, Oranges K, Smith S, Wegter ME, Militano O, Gupta S, Rau R, Zupanec S. Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children’s Oncology Group. Clin J Oncol Nurs. 2025 Aug 4;29(4):303-312. doi: 10.1188/25.CJON.303-312. PMID: 40794587; PMCID: PMC12339268.

The addition of blinatumomab to chemotherapy is the new standard of care for most pediatric patients with B-lineage acute lymphoblastic leukemia (B-ALL), and its use has increased rapidly. Administering blinatumomab to pediatric patients is associated with a spectrum of unique challenges, resulting in variable practices across institutions. This article presents expert recommendations for blinatumomab administration in patients with pediatric B-ALL.